Clinical Trial Update: A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial comparing TDF/FTC/RPV to TDF/FTC/EFV in HIV-1 patients with undetectable viral load on first-line therapy; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• TDF/FTC/EFV
• TDF/FTC/RPV

Snippet

Sponsor: Janssen-Cilag International NV | Conditions: Human Immunodeficiency Virus-type 1 Infection | Phase 3 | Status: COMPLETED | Results posted: 2017-01-05